Clinical manifestations of Niemann-Pick type C1 (NP-C1) disease include neonatal hepatosplenomegaly and in some patients progressive liver dysfunction and failure. This study involved a H NMR-linked metabolomics analysis of liver samples collected from a NP-C1 disease mutant mouse model in order to explore time-dependent imbalances in metabolic pathways associated with NP-C1 liver dysfunction, including fibrosis. NP-C1 mutant (Npc1; NP-C1), control (Npc1; WT), and NP-C1 heterozygous mice (Npc1; HET) were generated from heterozygote matings. Aqueous extracts of these liver samples collected at time points of 3, 6, 9, and 11 weeks were subjected to high-resolution NMR analysis, and multivariate (MV) metabolomics analyses of data sets acquired were performed. A MV random forests (RFs) model effectively discriminated between NP-C1 and a combined WT/HET hepatic NMR profiles with very high predictive accuracy and reliability. Key distinguishing features included significant upregulations in the hepatic concentrations of phenylalanine, tyrosine, glutamate, lysine/ornithine, valine, threonine, and hypotaurine/methionine, and diminished levels of nicotinate/niacinamide, inosine, phosphoenolpyruvate, and 3-hydroxyphenylacetate. Quantitative pathway topological analysis confirmed that imbalances in tyrosine biosynthesis, and hepatic phenylalanine, tyrosine, glutamate/glutamine, and nicotinate/niacinamide metabolism were involved in the pathogenesis of NP-C1 disease-associated liver dysfunction/damage. H NMR-linked metabolomics analysis provides valuable biomarker information regarding hepatic dysfunction or damage in NP-C1 disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jproteome.6b00238 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in research on potential therapeutic approaches for Niemann-Pick C1 disease.
Front Pharmacol
August 2024
Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Article Synopsis
- - Niemann-Pick disease type C1 (NP-C1) is a rare genetic disorder caused by mutations in the NPC1 or NPC2 genes, leading to issues with cholesterol transport and resulting in symptoms like enlarged liver and spleen, neurodegeneration, and loss of motor control.
- - Although NP-C1 is rare, researchers have been actively working on various potential therapies over the past 20 years, which include small molecule treatments, cell-based methods, and gene therapy.
- - The development of these treatments is still in the early experimental stages, presenting complex challenges that researchers aim to address in order to slow the disease's progression.
Beneficial in vitro effect of N-acetylcysteine and coenzyme Q10 on DNA damage in neurodegenerative Niemann-Pick type C 1 disease: preliminary results.
Naunyn Schmiedebergs Arch Pharmacol
July 2023
Programa de Pós-Graduação Em Ciências Farmacêuticas, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil.
Niemann-Pick type C1 (NP-C1) is a lysosomal storage disease (LSD) caused by mutations in NPC1 gene that lead to defective synthesis of the respective lysosomal transporter protein and cholesterol accumulation in late endosomes/lysosomes (LE/L) compartments, as well as glycosphingolipids GM2 and GM3 in the central nervous system (CNS). Clinical presentation varies according to the age of onset and includes visceral and neurological symptoms, such as hepatosplenomegaly and psychiatric disorders. Studies have been associating the pathophysiology of NP-C1 with oxidative damage to lipids and proteins, as well as evaluating the benefits of adjuvant therapy with antioxidants for this disease.
View Article and Find Full Text PDFmRNA Treatment Rescues Niemann-Pick Disease Type C1 in Patient Fibroblasts.
Mol Pharm
November 2022
Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.
Messenger RNA (mRNA) holds great potential as a disease-modifying treatment for a wide array of monogenic disorders. Niemann-Pick disease type C1 (NP-C1) is an ultrarare monogenic disease that arises due to loss-of-function mutations in the gene, resulting in the entrapment of unesterified cholesterol in the lysosomes of affected cells and a subsequent reduction in their capacity for cholesterol esterification. This causes severe damage to various organs including the brain, liver, and spleen.
View Article and Find Full Text PDFImpact of Organelle Transport Deficits on Mitophagy and Autophagy in Niemann-Pick Disease Type C.
Cells
February 2022
Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, 18147 Rostock, Germany.
Defective mitochondria are pathophysiological features of a number of neurodegenerative diseases. Here, we investigated mitochondrial dysfunction in the context of the rare lysosomal storage diseases Niemann-Pick disease type C1 and type C2 (NP-C1 and NP-C2). Mutations in either the or gene lead to cholesterol accumulation in late endosomes and lysosomes, resulting in impaired cholesterol homeostasis.
View Article and Find Full Text PDFAssessment of FDA-Approved Drugs as a Therapeutic Approach for Niemann-Pick Disease Type C1 Using Patient-Specific iPSC-Based Model Systems.
Cells
January 2022
Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, 18147 Rostock, Germany.
Niemann-Pick type C1 (NP-C1) is a fatal, progressive neurodegenerative disease caused by mutations in the gene. Mutations of can result in a misfolded protein that is subsequently marked for proteasomal degradation. Such loss-of-function mutations lead to cholesterol accumulation in late endosomes and lysosomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!